190 related articles for article (PubMed ID: 37310811)
1. Oncostatin-M and OSM-Receptor Feed-Forward Activation of MAPK Induces Separable Stem-like and Mesenchymal Programs.
Polak KL; Tamagno I; Parameswaran N; Smigiel J; Chan ER; Yuan X; Rios B; Jackson MW
Mol Cancer Res; 2023 Sep; 21(9):975-990. PubMed ID: 37310811
[TBL] [Abstract][Full Text] [Related]
2. Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer.
Smigiel JM; Parameswaran N; Jackson MW
Mol Cancer Res; 2017 Apr; 15(4):478-488. PubMed ID: 28053127
[TBL] [Abstract][Full Text] [Related]
3. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M.
Yu Z; Li Z; Wang C; Pan T; Chang X; Wang X; Zhou Q; Wu X; Li J; Zhang J; Liu B; Zhu Z; Su L
Gastric Cancer; 2019 Sep; 22(5):955-966. PubMed ID: 30778797
[TBL] [Abstract][Full Text] [Related]
4. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer.
West NR; Murray JI; Watson PH
Oncogene; 2014 Mar; 33(12):1485-94. PubMed ID: 23584474
[TBL] [Abstract][Full Text] [Related]
5. LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma.
Zhu YX; Li CH; Li G; Feng H; Xia T; Wong CH; Fung FKC; Tong JH; To KF; Chen R; Chen Y
Cell Mol Gastroenterol Hepatol; 2020; 10(4):811-828. PubMed ID: 32615164
[TBL] [Abstract][Full Text] [Related]
6. Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.
Kucia-Tran JA; Tulkki V; Scarpini CG; Smith S; Wallberg M; Paez-Ribes M; Araujo AM; Botthoff J; Feeney M; Hughes K; Caffarel MM; Coleman N
J Pathol; 2018 Mar; 244(3):283-295. PubMed ID: 29205362
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival.
Kucia-Tran JA; Tulkki V; Smith S; Scarpini CG; Hughes K; Araujo AM; Yan KY; Botthof J; Pérez-Gómez E; Quintanilla M; Cuschieri K; Caffarel MM; Coleman N
Br J Cancer; 2016 Jul; 115(2):212-22. PubMed ID: 27351213
[TBL] [Abstract][Full Text] [Related]
8. Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis.
Lee BY; Hogg EKJ; Below CR; Kononov A; Blanco-Gomez A; Heider F; Xu J; Hutton C; Zhang X; Scheidt T; Beattie K; Lamarca A; McNamara M; Valle JW; Jørgensen C
Nat Commun; 2021 Dec; 12(1):7336. PubMed ID: 34921158
[TBL] [Abstract][Full Text] [Related]
9. STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.
Bryson BL; Junk DJ; Cipriano R; Jackson MW
Cell Cycle; 2017 Feb; 16(4):319-334. PubMed ID: 27892764
[TBL] [Abstract][Full Text] [Related]
10. Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment.
Dinca SC; Greiner D; Weidenfeld K; Bond L; Barkan D; Jorcyk CL
Breast Cancer Res; 2021 May; 23(1):56. PubMed ID: 34011405
[TBL] [Abstract][Full Text] [Related]
11. Oncostatin-M differentially regulates mesenchymal and proneural signature genes in gliomas via STAT3 signaling.
Natesh K; Bhosale D; Desai A; Chandrika G; Pujari R; Jagtap J; Chugh A; Ranade D; Shastry P
Neoplasia; 2015 Feb; 17(2):225-37. PubMed ID: 25748242
[TBL] [Abstract][Full Text] [Related]
12. Breaking the oncostatin M feed-forward loop to suppress metastasis and therapy failure.
Smigiel J; Parvani JG; Tamagno I; Polak K; Jackson MW
J Pathol; 2018 May; 245(1):6-8. PubMed ID: 29473175
[TBL] [Abstract][Full Text] [Related]
13. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition.
Guo L; Chen C; Shi M; Wang F; Chen X; Diao D; Hu M; Yu M; Qian L; Guo N
Oncogene; 2013 Nov; 32(45):5272-82. PubMed ID: 23318420
[TBL] [Abstract][Full Text] [Related]
14. Oncostatin M: Dual Regulator of the Skeletal and Hematopoietic Systems.
Sims NA; Lévesque JP
Curr Osteoporos Rep; 2024 Feb; 22(1):80-95. PubMed ID: 38198032
[TBL] [Abstract][Full Text] [Related]
15. JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.
Shien K; Papadimitrakopoulou VA; Ruder D; Behrens C; Shen L; Kalhor N; Song J; Lee JJ; Wang J; Tang X; Herbst RS; Toyooka S; Girard L; Minna JD; Kurie JM; Wistuba II; Izzo JG
Mol Cancer Ther; 2017 Oct; 16(10):2234-2245. PubMed ID: 28729401
[TBL] [Abstract][Full Text] [Related]
16. Oncostatin m modulates the mesenchymal-epithelial transition of lung adenocarcinoma cells by a mesenchymal stem cell-mediated paracrine effect.
Wang ML; Pan CM; Chiou SH; Chen WH; Chang HY; Lee OK; Hsu HS; Wu CW
Cancer Res; 2012 Nov; 72(22):6051-64. PubMed ID: 23139208
[TBL] [Abstract][Full Text] [Related]
17. Oncostatin M is a growth factor for Ewing sarcoma.
David E; Tirode F; Baud'huin M; Guihard P; Laud K; Delattre O; Heymann MF; Heymann D; Redini F; Blanchard F
Am J Pathol; 2012 Nov; 181(5):1782-95. PubMed ID: 22982441
[TBL] [Abstract][Full Text] [Related]
18. Oncostatin M regulates SOCS3 mRNA stability via the MEK-ERK1/2-pathway independent of p38(MAPK)/MK2.
Ehlting C; Böhmer O; Hahnel MJ; Thomas M; Zanger UM; Gaestel M; Knoefel WT; Schulte Am Esch J; Häussinger D; Bode JG
Cell Signal; 2015 Mar; 27(3):555-67. PubMed ID: 25562430
[TBL] [Abstract][Full Text] [Related]
19. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
Doherty MR; Parvani JG; Tamagno I; Junk DJ; Bryson BL; Cheon HJ; Stark GR; Jackson MW
Breast Cancer Res; 2019 Apr; 21(1):54. PubMed ID: 31036052
[TBL] [Abstract][Full Text] [Related]
20. Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts.
Le Goff B; Singbrant S; Tonkin BA; Martin TJ; Romas E; Sims NA; Walsh NC
Cytokine; 2014 Aug; 68(2):101-9. PubMed ID: 24767864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
